Tag Archive for: Poolbeg Pharma

Poolbeg Pharma plc – POLB 001 Patent Granted in United States

/in

Further strengthens Poolbeg’s robust intellectual property portfolio 20 November 2024- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focused on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that the US Patent Office has notified the Company of its official decision to grant Poolbeg’s US Immunomodulator I […]

Read more

Poolbeg Pharma plc to present POLB 001 pre-clinical study data at the 66th American Society of Hematology (ASH) Annual Meeting

/in

POLB 001 Reduces Cytokine Release Syndrome (CRS) in an in vivo animal model Positive results reinforce POLB 001’s potential in the prevention and treatment of cancer immunotherapy-induced CRS ASH is the world’s premier conference focussing on haematological malignancies 6 November 2024 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company focussed on the development […]

Read more

Poolbeg Pharma plc – Interim results for the six months to 30 June 2024

/in

Lead development candidate (POLB 001) on track with positive data demonstrating efficacy Independent research endorses potential US$10bn market opportunity for POLB 001 in cancer immunotherapy-induced CRS Patent portfolio significantly strengthened & expanded Continued focus on high value programmes & partnerships to develop & commercialise assets Strong Balance Sheet – cash balance of £10.1m Experienced leadership team with track […]

Read more

Poolbeg Pharma plc – Significant POLB 001 Patent Granted in United States

/in

Immunomodulator II patent grant further strengthens robust intellectual property portfolio for partnering 1 May 2024 - Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that, further to its announcement on 20 March 2024, the Company has received the fully […]

Read more

Poolbeg Pharma plc – Exclusive Option Agreement to Acquire Orphan Drug Candidate for Behçet’s Disease

/in

Novel therapeutic with Fast Track and Orphan Designation 30 April 2024 – Poolbeg Pharma (AIM: POLB, OTCQB: POLBF, ‘Poolbeg’ or the ‘Company’), a biopharmaceutical company focussed on the development and commercialisation of innovative medicines targeting diseases with a high unmet medical need, announces that it has entered into an exclusive 12-month option agreement with Silk Road Therapeutics Inc,  for […]

Read more
© Optimum Strategic Communications.